Observational studyFrontiers in immunology2026
Case report: The masquerading spectrum: a pediatric case series of IgG4-related disease.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory condition with scarce data on its clinical spectrum and management in the pediatric population.We present a single-center observational study of six children with clinically and morphologically confirmed IgG4-RD. We analyzed the age of onset, time to diagnosis, and comprehensive clinical, imaging, laboratory, and histopathological findings at presentation and during follow-up (range: 3 months to 7 years). The 2020 revised comprehensive diagnostic criteria for IgG4-RD were used. The diagnosis was based on a biopsy of orbital tissue with detection of signs of fibrosis, obliterating phlebitis, and subsequent immunohistochemical testing for the presence of IgG4. The disease manifested itself in 4 patients with orbital pseudotumor, in 1 patient with diabetes insipidus, in 1 patient with fever, signs of high inflammatory and immunological activity. The diagnostic delay ranged from 3 to 12 months. Treatment regimens included glucocorticoids combined with cytostatic agents (n=3), cytostatic monotherapy (n=2), and initial glucocorticoid monotherapy (n=1). Three patients achieved a good clinical and radiological response without disease progression. One patient experienced multiple relapses while on topical steroid therapy, which were successfully controlled after switching to systemic cytostatic therapy. Two children achieved incomplete remission. They were advised to continue rituximab therapy. This case series underscores the diagnostic challenge and phenotypic diversity of pediatric IgG4-RD. The most common clinical manifestation in our patients was orbital involvement. Prednisone and cytostatic agents were effective for inducing and maintaining remission. Our findings contribute to the evolving understanding of this rare condition in childhood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.